title: Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin.
abstract: BACKGROUND
  The genus Nairovirus in the family Bunyaviridae contains 34 tick-borne viruses classified into seven serogroups. Hazara virus (HAZV) belongs to the Crimean-Congo hemorrhagic fever (CCHF) serogroup that also includes CCHF virus (CCHFV) a major pathogen for humans. HAZV is an interesting model to study CCHFV due to a close serological and phylogenetical relationship and a classification which allows handling in a BSL2 laboratory. Nairoviruses are characterized by a tripartite negative-sense single stranded RNA genome (named L, M and S segments) that encode the RNA polymerase, the Gn-Gc glycoproteins and the nucleoprotein (NP), respectively. Currently, there are neither vaccines nor effective therapies for the treatment of any bunyavirus infection in humans. In this study we report, for the first time, the use of RNA interference (RNAi) as an approach to inhibit nairovirus replication.
  
  
  RESULTS
  Chemically synthesized siRNAs were designed to target the mRNA produced by the three genomic segments. We first demonstrated that the siRNAs targeting the NP mRNA displayed a stronger antiviral effect than those complementary to the L and M transcripts in A549 cells. We further characterized the two most efficient siRNAs showing, that the induced inhibition is specific and associated with a decrease in NP synthesis during HAZV infection. Furthermore, both siRNAs depicted an antiviral activity when used before and after HAZV infection. We next showed that HAZV was sensitive to ribavirin which is also known to inhibit CCHFV. Finally, we demonstrated the additive or synergistic antiviral effect of siRNAs used in combination with ribavirin.
  
  
  CONCLUSIONS
  Our study highlights the interest of using RNAi (alone or in combination with ribavirin) to treat nairovirus infection. This approach has to be considered for the development of future antiviral compounds targeting CCHFV, the most pathogenic nairovirus.
authors: Unité de virologie, Institut de Recherche Biomédicale des Armées, 24 avenue des Maquis du Grésivaudan, La Tronche, France. o.flusin@crssa.net
authors: Olivier
authors: O
authors: Flusin
authors: Solenne
authors: S
authors: Vigne
authors: Christophe N
authors: CN
authors: Peyrefitte
authors: Michèle
authors: M
authors: Bouloy
authors: Jean-Marc
authors: JM
authors: Crance
authors: Frédéric
authors: F
authors: Iseni
references: Acta Virol. 1978 Jan;22(1):77
references: 25013
references: J Virol. 2003 Jul;77(13):7174-81
references: 12805416
references: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8676-81
references: 15173599
references: J Med Entomol. 1979 May 22;15(4):307-417
references: 113533
references: Nature. 1998 Feb 19;391(6669):806-11
references: 9486653
references: Antimicrob Agents Chemother. 2009 Jun;53(6):2579-88
references: 19307376
references: Euro Surveill. 2010 Mar 11;15(10):19504
references: 20403306
references: Int J Infect Dis. 2011 Jan;15(1):e44-7
references: 21106428
references: Nat Cell Biol. 2003 Sep;5(9):834-9
references: 12942087
references: Adv Drug Deliv Rev. 2007 Oct 10;59(12):1263-76
references: 17822803
references: Antiviral Res. 2004 Dec;64(3):145-60
references: 15550268
references: Antimicrob Agents Chemother. 2008 Jun;52(6):2111-9
references: 18378711
references: Antivir Ther. 2009;14(5):655-62
references: 19704168
references: Nature. 2002 Jul 25;418(6896):435-8
references: 12087358
references: Genes Dev. 2001 Jan 15;15(2):188-200
references: 11157775
references: Virus Res. 2006 Sep;120(1-2):121-7
references: 16616390
references: Mol Ther. 2003 Nov;8(5):769-76
references: 14599810
references: Virol J. 2009 Nov 04;6:188
references: 19889227
references: Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24
references: 17724153
references: Acta Virol. 1977 Mar;21(2):128-32
references: 17280
references: J Infect. 2009 Oct;59(4):284-6; author reply 286-9
references: 19699762
references: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2014-8
references: 12566571
references: Am J Epidemiol. 1970 Sep;92(3):197-202
references: 5458948
references: Lancet Infect Dis. 2006 Apr;6(4):203-14
references: 16554245
references: J Gen Virol. 2000 Sep;81(Pt 9):2161-2166
references: 10950972
references: Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8682-6
references: 15173583
references: Clin Infect Dis. 2009 Nov 15;49(10):1621-2
references: 19857172
references: Nat Biotechnol. 2005 Apr;23(4):457-62
references: 15778705
references: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4187-91
references: 8633038
references: Trans R Soc Trop Med Hyg. 1983;77(4):446-50
references: 6415873
references: FEBS Lett. 2005 Oct 31;579(26):5822-9
references: 16214139
references: Virology. 2004 Jan 5;318(1):10-6
references: 14972529
references: FEBS Lett. 2003 May 22;543(1-3):51-4
references: 12753904
references: Virol J. 2010 Nov 13;7:318
references: 21073745
references: Nucleic Acids Res. 2006;34(16):4467-76
references: 16945958
references: Antiviral Res. 2009 Sep;83(3):274-81
references: 19576249
references: J Med Virol. 2005 Sep;77(1):83-8
references: 16032715
references: J Gen Virol. 2005 Apr;86(Pt 4):1181-1188
references: 15784912
references: Nat Biotechnol. 2005 Aug;23(8):1002-7
references: 16041363
references: J Virol. 2006 Sep;80(17):8834-42
references: 16912331
references: Antiviral Res. 1993 Dec;22(4):309-25
references: 8279818
references: Hepatology. 2005 Jun;41(6):1349-56
references: 15880588
references: Virol J. 2005 Apr 25;2:42
references: 15850490
references: J Virol. 2005 Jul;79(14):8942-7
references: 15994788
references: Retrovirology. 2010 Jun 08;7:52
references: 20529316
references: Nat Med. 2005 Jan;11(1):50-5
references: 15619632
references: Travel Med Infect Dis. 2010 May;8(3):139-43
references: 20541133
references: Cell. 2008 Aug 22;134(4):577-86
references: 18691745
references: Sci Transl Med. 2010 Jun 16;2(36):36ra43
references: 20555022
references: Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800-5
references: 20421463
references: Lancet. 2010 May 29;375(9729):1896-905
references: 20511019
references: Trends Immunol. 2005 May;26(5):238-9; discussion 239-41
references: 15866234
references: Antiviral Res. 2008 Mar;77(3):225-31
references: 18242722
references: Med Trop (Mars). 2010 Dec;70(5-6):429-38
references: 21520641
references: Antivir Ther. 2008;13(3):357-68
references: 18572748
references: J Infect Dis. 2006 Jun 15;193(12):1650-7
references: 16703508
references: Curr Top Microbiol Immunol. 1991;169:91-141
references: 1935231
references: Antiviral Res. 2008 Apr;78(1):125-31
references: 18096251
references: J Gastroenterol Hepatol. 2008 Sep;23(9):1437-47
references: 17683479
references: Infect Genet Evol. 2009 Sep;9(5):948-54
references: 19560561
references: J Virol. 2005 Jan;79(1):234-44
references: 15596819
references: Antiviral Res. 2007 Jan;73(1):24-30
references: 16844238
references: Nucleic Acids Res. 2007;35(15):5154-64
references: 17660190
references: Nat Biotechnol. 2003 Jun;21(6):639-44
references: 12740585
references: J Biomed Biotechnol. 2006;2006(4):63675
references: 17057365
references: J Biomed Sci. 2003;10(6 Pt 1):607-16
references: 14576463
references: J Gen Virol. 1981 Mar;53(Pt 1):169-72
references: 7276913
references: J Virol. 2010 Nov;84(21):11089-100
references: 20739514
references: J Virol. 2003 Jan;77(1):810-2
references: 12477890
references: Am J Trop Med Hyg. 1989 Nov;41(5):581-5
references: 2510529